➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Moodys
Harvard Business School
McKinsey
AstraZeneca

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Amifampridine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for amifampridine and what is the scope of patent protection?

Amifampridine is the generic ingredient in two branded drugs marketed by Jacobus Pharm Co Inc and Catalyst Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for amifampridine
US Patents:0
Tradenames:2
Applicants:2
NDAs:2
Suppliers / Packagers: 1
Bulk Api Vendors: 155
Clinical Trials: 8
Patent Applications: 1,624
DailyMed Link:amifampridine at DailyMed
Recent Clinical Trials for amifampridine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Catalyst Pharmaceuticals, Inc.Phase 2
Catalyst Pharmaceuticals, Inc.Phase 3
Catalyst Pharmaceuticals, Inc.N/A

See all amifampridine clinical trials

Generic filers with tentative approvals for AMIFAMPRIDINE
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial10MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for amifampridine

US Patents and Regulatory Information for amifampridine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Catalyst Pharms FIRDAPSE amifampridine phosphate TABLET;ORAL 208078-001 Nov 28, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Catalyst Pharms FIRDAPSE amifampridine phosphate TABLET;ORAL 208078-001 Nov 28, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Jacobus Pharm Co Inc RUZURGI amifampridine TABLET;ORAL 209321-001 May 6, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Colorcon
Baxter
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.